2-219157471-C-T
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_StrongPS3PM2PP5_Moderate
The NM_024782.3(NHEJ1):c.390+1G>A variant causes a splice donor, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★). ClinVar reports functional evidence for this variant: "SCV003235486: Studies have shown that disruption of this splice site is associated with altered splicing resulting in multiple RNA products (PMID:28741180).".
Frequency
Consequence
NM_024782.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- Cernunnos-XLF deficiencyInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_024782.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| NHEJ1 | TSL:1 MANE Select | c.390+1G>A | splice_donor intron | N/A | ENSP00000349313.5 | Q9H9Q4-1 | |||
| ENSG00000280537 | TSL:2 | n.*1512+1G>A | splice_donor intron | N/A | ENSP00000320919.3 | F8W735 | |||
| NHEJ1 | c.390+1G>A | splice_donor intron | N/A | ENSP00000551167.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.